We are building a portfolio of novel programmes in cancer, spanning early stage discovery up to early clinical trials, through a combination of in-house discovery and in-licensing.
We aim to create a unique intellectual property position and will generally seek to retain ownership of our key programmes until we have demonstrated proof of concept in man, and to identify potential partners for non-core programmes at an earlier stage. However we have a very flexible approach to partnering and deal structures, and are happy to entertain partnering discussions on any of our programmes at any time.
We are interested in talking to academic and industry collaborators who have novel, small molecule cancer programmes for which they are seeking partners, particularly in our core areas of interest in targeted DNA damage and DNA repair inhibition.
We are interested in talking to potential partners about our PMX 500 and PMX 700 programmes.
We regularly attend key academic and industry life sciences conferences. Please click here for information about Pharminox attendance at specific events.